Icecure Medical Ltd (NAS:ICCM)

Q1 2025 Icecure Medical Ltd Earnings Call Transcript

May 28, 2025 / 02:00 PM GMT

Release Date Price: $30.32 (-8.85%)

Transcript

Key Points

Positve

Icecure Medical Ltd (ICCM) has submitted a postmarket study plan to the FDA, which is a significant milestone towards obtaining marketing authorization for their cryoablation technology.
The company experienced growth in sales in North America and Europe, with an 11% increase in North America and a 60% increase in Europe year-over-year.
Icecure Medical Ltd (ICCM) has strong support from its largest shareholder, who provided a $2 million unsecured loan, demonstrating confidence in the company's technology and business plan.
The company is optimistic about potential FDA marketing authorization, which would allow them to commence commercial sales and access reimbursement under the CPT code.
There is a high level of interest from breast surgeons and interventional radiologists in participating in the planned post-market study, indicating strong market interest in the technology.

Negative

Revenue for the first quarter of 2025 was $725,000, a slight decrease from $743,000 in the same period in 2024.
Gross profit and gross margin both declined, with gross profit at $218,000 compared to $269,000 the previous year, and gross margin dropping from 36% to 30%.
Sales in Asia declined significantly, with a 60% decrease in Japan and a 40% decrease in other parts of Asia.
The company reported a net loss of $3.59 million for the quarter, slightly less than the $3.61 million loss in the previous year.
The FDA has not provided a specific timeline for the review of the postmarket study plan, creating uncertainty around the timing of potential marketing authorization.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ICCM.OQ - Icecure Medical Ltd
Q1 2025 Icecure Medical Ltd Earnings Call
May 28, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and thank you for standing by. Currently all the participants are in a listen-only mode. After management's discussion, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Michael Poliview. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Janni, and welcome to ISecure Medical's conference call to review the financial results as of and for the three months ended March 31, 2025 and provide an update on recent operational highlights. You may refer

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.